Larimar Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -74 | -87 | -80 | -81 |
EBITDA | -18,264 | -24,512 | -16,654 | -14,081 |
EBIT | -18,338 | -24,599 | -16,734 | -14,162 |
Net Income | -15,499 | -21,627 | -14,654 | -12,993 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -24,608 | -14,262 | -10,411 | -9,507 |
Cash | 35,067 | 32,311 | 110,125 | 26,749 |
Basic Shares | 63,806 | 63,801 | 53,553 | 43,905 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -311 | -272 | -326 | -155 |
EBITDA | -41,447 | -36,208 | -50,139 | -42,649 |
EBIT | -41,758 | -36,526 | -50,465 | -42,804 |
Net Income | -36,949 | -34,184 | -50,310 | -42,327 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -43,272 | 68,478 | ||
Free Cash Flow | -33,623 | -27,669 | -42,438 | -42,261 |
Cash | 26,749 | 26,825 | 70,097 | 68,148 |
Basic Shares | 43,901 | 25,761 | 17,164 | 11,883 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.24 |
2024-06-30 | -$0.34 |
2024-03-31 | -$0.27 |
2023-12-31 | -$0.30 |
